Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jan 9;16(3):494–505. doi: 10.1158/1535-7163.MCT-16-0315-T

Figure 5.

Figure 5

ML115 protects against cancer induced osteolysis and promotes tumor apoptosis. A, Multiple sections from tumor bearing limbs in control (CTRL), ML115 and zoledronate (ZOL) treated groups were generated and trichrome stained. The trabecular bone volume (BV, dashed lines) was measured as a ratio to total volume (TV). B, The total number of multinucleated osteoclasts/cells (pink; arrows) per mm of tumor-bone interface was calculated in tissue sections derived from each group. C, D, The proliferative index (pHistone-H3 positive (red): total number of cells) and apoptotic index (cleaved caspase-3 positive (red, arrows): total number of cells) was calculated for each group. Panels show representative images from the control (CTRL), ML115 and ZOL groups. Asterisks denote statistical significance (**, p<0.01).